August 14, 2026

Lantern Pharma Advances AI-Driven Oncology Pipeline, Spins Out Open Medicine AI

August 7, 2026

Lantern Pharma to Report Q2 2026 Results, Highlight AI Platform Progress

July 23, 2026

Lantern Pharma Receives U.S. Patent Allowance for LP-184 Biomarker-Based Treatment Methods